Abstract:The loss of vascular wall cells in allotransplanted arteries is the initial event leading to transplant arteriosclerosis (TA) and ensuing loss of allograft function. Pharmacological agents able to prevent TA are currently lacking. We previously showed that selective inhibition of the immunoproteasome prevented the chronic rejection of renal allografts. However, the role and mechanisms of selective inhibition of a single immunoproteasome subunit suffices to prevent immune-mediated vascular allograft rejection and TA is not clear. The effect and potential mechanism of combined or individual inhibition of peptidolytically active immunoproteasome LMP7 (β5i) and LMP2 (β1i) subunits on immune rejection-mediated TA was investigated using the epoxyketone inhibitor ONX 0914, and the recently developed LMP7-selective inhibitor KZR-329 and LMP2-selective inhibitor KZR-504 in a rat aorta transplantation model. We find that co-inhibition of LMP7 and LMP2 in allogeneic recipients significantly suppressed T cell activation and function by expressing inhibitory surface markers and then activating inhibitory signals. Moreover, co-inhibition of LMP7 and LMP2 substantially reduced the number of IgG secreting cells and plasma cells and production of alloantibodies through activating the unfolded protein response and incapacitating the survival niche of plasma cells in the bone marrow. Consequentially, the accumulation of inflammatory cytokines, complement and antibodies is reduced and the apoptosis of vascular wall cells decreased in aortic allografts via LMP7 and LMP2 co-inhibition with ONX 0914 treatment or combined KZR-329 and KZR-504 treatment. However, neither individual inhibition of LMP7 by KZR-329 nor individual inhibition of LMP2 by KZR-504 showed suppression of immune rejection and TA. We define a critical role of LMP7 and LMP2 in TA and strongly propose co-inhibition of both immunoproteasome subunits as promising therapeutic approach to suppress TA and allograft rejection. So far, effective pharmacological agents to treat transplant arteriosclerosis and ensuing chronic allograft rejection are lacking. Co-inhibition, but neither individual inhibition, of peptidolytically active immunoproteasome LMP7 and/nor LMP2 subunits using epoxyketone inhibitors significantly prevents transplant arteriosclerosis by suppressing T cell-mediated and humoral immune rejection. LMP7 and LMP2 are identified as targets for the prevention of chronic immune rejection after transplantation. Pharmaceuticals that co-inhibit immunoproteasome subunits are currently clinically tested as drugs against autoimmunity. These drugs hold great promise for suppressing transplant arteriosclerosis and allograft rejection, potentially improving prognosis of patients after solid organ transplantation.

The endogenous pro-resolving mediators lipoxin A4 and resolvin E1 preserve organ function in allograft rejection

Inflammasome Activation Involved in Early Inflammation Reaction after Liver Transplantation.

Ex Vivo Anchored PD‐L1 Functionally Prevent in Vivo Renal Allograft Rejection

Resolvin D1 prevents injurious neutrophil swarming in transplanted lungs

Resolution of post-lung transplant ischemia-reperfusion injury is modulated via Resolvin D1-FPR2 and Maresin 1-LGR6 signaling

Lipoxin A4 mitigates ferroptosis via FPR2 signaling during lung ischemia-reperfusion injury

Scr1slex Ameliorates Ischemia/reperfusion Injury in Experimental Lung Transplantation

Lipoxin A4 attenuates the lung ischaemia reperfusion injury in rats after lung transplantation

STABLE EXPRESSION OF INTERLEUKIN-10 SUPPRESSES THE DEVELOPMENT OF CHRONIC ALLOGRAFT REJECTION IN RATS:

Transcriptomic Analysis of Graft Liver Provides Insight into the Immune Response of Rat Liver Transplantation

Lymphotoxin β receptor and tertiary lymphoid organs shape acute and chronic allograft rejection

Co-inhibition of immunoproteasome subunits LMP2 and LMP7 enables prevention of transplant arteriosclerosis

Early Protection by Resveratrol in Rat Lung Transplantation

Blocking hyaluronan synthesis alleviates acute lung allograft rejection

Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators

Effect of soluble complement receptor type 1 on reperfusion edema and neutrophil migration after lung allotransplantation in swine

Increased Expression of Non-Interleukin-2 T Cell Growth Factors and Their Implications During Liver Allograft Rejection in Rats

Expression of Hemopexin in Acute Rejection of Rat Liver Allograft Identified by Serum Proteomic Analysis.

Involvement of ischemia-driven 5-lipoxygenase-resolvin-E1-chemokine like receptor-1 axis in the resolution of post-coronary artery bypass graft inflammation in coronary arteries

Ischemia reperfusion injury facilitates lung allograft acceptance through IL-33-mediated activation of donor-derived IL-5 producing group 2 innate lymphoid cells

Transduction of Interleukin-10 Through Renal Artery Attenuates Vascular Neointimal Proliferation and Infiltration of Immune Cells in Rat Renal Allograft.